超重与转移性结直肠癌更好预后相关:FFCD 试验汇总分析
该汇总分析纳入 1991 至 2013 年八项 FFCD 一线转移性结直肠癌试验的 2085 例患者个体数据,按 BMI 分层比较疗效。超重患者(BMI≥25)较正常 BMI 患者中位总生存显著改善(18.5 对 16.3 个月,HR=0.88,p=0.02),客观缓解率更高(42% 对 36%,OR=1.23,p=0.04),中位无进展生存无显著差异。亚组分析显示超重与更好 OS 的关联仅在男性中显著,BMI<18.5 者 OS 与 PFS 均显著缩短。
要点
- 超重(BMI≥25)mCRC 患者中位 OS 优于正常 BMI 者(18.5 对 16.3 个月,HR=0.88)。
- 超重者 ORR 更高(42% 对 36%,OR=1.23),但 PFS 无显著差异。
- 超重与更好 OS 的关联仅在男性中显著,BMI<18.5 者预后更差。
核心结论
- 超重转移性结直肠癌患者较正常体重患者总生存延长。
- 超重与更好 OS 的关联仅在男性中观察到。
- BMI<18.5 的不良预后得到确认。
研究设计与样本
- 汇总分析八项 FFCD 一线 mCRC 试验(1991–2013 年)2085 例患者个体数据。
- 按 BMI 切点分组:肥胖(≥30)、超重(≥25)、正常(18.5–24)、消瘦(<18.5)。
- 对 BMI 效应与性别、年龄及化疗联合抗血管生成治疗进行交互检验。
主要发现
- BMI≥25 患者占 41.5%,从 1991–1999 年的 37.6% 升至 2007–2013 年的 44.8%。
- 亚组分析显示超重与更好 OS 的关联仅在男性中显著,消瘦者 OS 与 PFS 均显著缩短。
临床怎么用
- 评估 mCRC 患者预后时可参考基线 BMI,消瘦(<18.5)提示预后不良。
- 超重与更好 OS 的关联需结合性别解读,不宜据此改变治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI was associated with worse prognosis in metastatic CRC (mCRC). We aimed to assess efficacy outcomes according to BMI. PATIENTS AND METHODS: A pooled analysis of individual data from 2085 patients enrolled in eight FFCD first-line mCRC trials from 1991 to 2013 was performed. Comparisons were made according to the BMI cut-off: Obese (BMI ≥30), overweight patients (BMI ≥ 25), normal BMI patients (BMI: 18.5-24) and thin patients (BMI <18.5). Interaction tests were performed between BMI effect and sex, age and the addition of antiangiogenics to chemotherapy. RESULTS: The rate of BMI ≥25 patients was 41.5%, ranging from 37.6% (1991-1999 period) to 41.5% (2000-2006 period) and 44.8% (2007-2013 period). Comparison of overweight patients versus normal BMI range patients revealed a significant improvement of median overall survival (OS) (18.5 versus 16.3 months, HR = 0.88 [0.80-0.98] p = 0.02) and objective response rate (ORR) (42% versus 36% OR = 1.23 [1.01-1.50] p = 0.04) but a comparable median progression-free survival (PFS) (7.8 versus 7.2 months, HR = 0.96 [0.87-1.05] p = 0.35). Subgroup analyses revealed that overweight was significantly associated with better OS in men. OS and PFS were significantly shorter in thin patients. CONCLUSION: Overweight patients had a prolonged OS compared with normal weight patients with mCRC. The association of overweight with better OS was only observed in men. The pejorative prognosis of BMI <18.5 was confirmed.
引用
- Aparicio T, Ducreux M, Faroux R, et al. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. Eur J Cancer. 2018. PMID: 29807237. doi:10.1016/j.ejca.2018.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。